Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Vulvovaginal candidiasis/candidosis is a common fungal infection afflicting approximately 75% of women globally caused primarily by the yeast Candida albicans. Fluconazole is widely regarded as the antifungal drug of choice since its introduction in 1990 due to its high oral bioavailability, convenient dosing regimen and favourable safety profile. However, its widespread use has led to the emergence of fluconazole-resistant C. albicans, posing a universal clinical concern. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 24, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Experience with the Platelia Candida ELISA for the diagnosis of invasive candidosis in neonatal patients
Oliveri S, Trovato L, Betta P, Romeo MG, Nicoletti G (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 5, 2013 Category: Respiratory Medicine Source Type: news